Through research and partnerships across the oncology community, we are committed to closing the gap in existing disparities in cancer care.


A new study in partnership with Dr. Gregory Vidal and our West family, OneOncology, Genentech, and Flatiron Health examined elements of inequity in next generation sequencing (NGS) for patients with advanced non-small cell lung cancer being treated in the community setting in the United States.


Dr. Gregory Vidal presented this information at #ASCO23 (American Society of Clinical Oncology‘s 2023 Conference) before physicians and researchers from across the country.


To read more about this study and oral presentation, please visit: